Cargando…

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Maliha, Saif, Areeba, Sandler, Steven, Mirrakhimov, Aibek E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003830/ https://www.ncbi.nlm.nih.gov/pubmed/25093123 http://dx.doi.org/10.1155/2014/931858

Ejemplares similares

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
por: Madanat, Yazan F, et al.
Publicado: (2016)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature
por: Mirrakhimov, Aibek E., et al.
Publicado: (2014)

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
por: Hock, Barry D., et al.
Publicado: (2017)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony
por: Mirrakhimov, Aibek E
Publicado: (2012)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Propofol Infusion Syndrome in Adults: A Clinical Update
por: Mirrakhimov, Aibek E., et al.
Publicado: (2015)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2020)

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia
por: Primo, Daniel, et al.
Publicado: (2018)

Hypercalcemia of Malignancy: An Update on Pathogenesis and Management
por: Mirrakhimov, Aibek E.
Publicado: (2015)

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
por: Schetelig, Johannes, et al.
Publicado: (2021)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Management of adverse events associated with idelalisib treatment: expert panel opinion
por: Coutré, Steven E., et al.
Publicado: (2015)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
por: Burke, Russell T, et al.
Publicado: (2014)

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects
por: Tariq, Saba, et al.
Publicado: (2020)

Papillary Serous Carcinoma of the Uterine Cervix with Lung Metastasis
por: Khan, Maliha, et al.
Publicado: (2014)

Primary Small Cell Neuroendocrine Carcinoma of Paranasal Sinuses
por: Khan, Maliha, et al.
Publicado: (2014)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K(δ) inhibitor idelalisib
por: Sandova, Veronika, et al.
Publicado: (2021)

Pathobiology of Obstructive Sleep Apnea-Related Dyslipidemia: Focus on the Liver
por: Mirrakhimov, Aibek E., et al.
Publicado: (2013)

Primary Anorectal Melanoma
por: Khan, Maliha, et al.
Publicado: (2014)

Clostridium perfringens Bacteremia in an 85-Year-Old Diabetic Man
por: Mirrakhimov, Aibek E., et al.
Publicado: (2014)

Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?
por: Mirrakhimov, Aibek E
Publicado: (2014)

Epidural Brain Metastases in a Patient with Early Onset Pancreatic Cancer: A Case Report and Literature Review
por: Mirrakhimov, Aibek E., et al.
Publicado: (2012)

Non drowsy obstructive sleep apnea as a potential cause of resistant hypertension: a case report
por: Mirrakhimov, Aibek E
Publicado: (2012)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Prevalence of obstructive sleep apnea in Asian adults: a systematic review of the literature
por: Mirrakhimov, Aibek E, et al.
Publicado: (2013)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib
por: Kang, Hyeonjeong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rnvgbp4g67fbmb3ah86pr5141s